All HHS Contracts — August 21, 2026

With $89.6 million (65%) of the $138.6 million delivery order already outlayed through September 2027, Highrise Consulting demonstrates robust execution and low cancellation risk, providing stable ~$27.7 million annual revenue.

The 10-year, $1.04 billion potential value contract (with $263.6 million obligated) for Marburg virus R&D highlights sustained BARDA commitment to biodefense, though the nonprofit recipient limits direct equity upside.

The Marburg virus contract runs through 2036, with only $263.6 million obligated upfront; option exercises depend on future budget cycles and BARDA priorities, creating long-term execution risk.

Both contracts were awarded in periods vulnerable to CR uncertainty (September 2022 and May 2026), potentially delaying option exercises or new task orders if Congress fails to pass appropriations.

The $138.6 million contract represents a significant portion of Highrise's likely revenue; any re-compete loss or budget cut would materially impact the company.

Highrise Consulting's $27.7 million annual revenue from NIH cloud support suggests growing demand for IT modernization services at civilian agencies, benefiting small business IT contractors.

The $1.04 billion Sabin contract could generate subcontract awards to publicly traded biotech companies for vaccine development, creating indirect investment opportunities.

Highrise Consulting's $138.6 million NIH delivery order for cloud and IT support, with 65% already outlayed, demonstrates sustained civilian agency investment in IT modernization, providing predictable revenue streams for small business contractors.

BARDA's $1.04 billion commitment to Sabin Vaccine Institute for Marburg virus R&D underscores sustained federal investment in pandemic preparedness, though the nonprofit awardee limits direct equity exposure.

{"entity" => "Highrise Consulting Inc", "reason" => "The $138.6 million NIH IT contract represents a significant revenue concentration; any re-compete loss would be material.", "trigger" => "Contract expiration in September 2027; re-compete announcement expected in late 2026 or early 2027"}

{"entity" => "Albert B. Sabin Vaccine Institute", "reason" => "The $263.6 million obligated under the 10-year BARDA contract is subject to option exercises; delays or cancellations would signal reduced biodefense funding.", "trigger" => "Option exercise announcements; BARDA budget updates; NDAA provisions for biodefense"}